In non-cirrhotic primary biliary cholangitis, fatigue burden is similar to healthy controls and primary sclerosing cholangitis, but its phenotype is predominantly muscular (approximately 69%), independent of sex, age-adjusted employment, or routine disease metrics; daytime sleepiness and sleep duration are low/normal, and chronotype clusters in the intermediate range, with age - not disease - driving greater morningness. Primary sclerosing cholangitis shows a similar (weaker) direction of effect. These findings support routine fatigue phenotyping and muscle-focused interventions over cholestasis-directed therapies, and argue for objective endpoints (e.g., 31phosphorus magnetic resonance spectroscopy, actigraphy) in future trials.
Fatigue and circadian rhythm in non-cirrhotic primary biliary cholangitis: An exploratory comparison with primary sclerosing cholangitis and healthy controls / Curto, A., Tanturli, M., Iamello, R.G., Rossi, P., Mengozzi, G., Dei, L., Mello, T., Innocenti, T., Dragoni, G., Galli, A., Lynch, E.N.. - In: WORLD JOURNAL OF HEPATOLOGY. - ISSN 1948-5182. - ELETTRONICO. - 18:(2026), pp. 0-0. [10.4254/wjh.v18.i2.114206]
Fatigue and circadian rhythm in non-cirrhotic primary biliary cholangitis: An exploratory comparison with primary sclerosing cholangitis and healthy controls
Curto, Armando;Tanturli, Michele;Iamello, Rocco Gabriele;Dei, Leonardo;Mello, Tommaso;Innocenti, Tommaso;Dragoni, Gabriele;Galli, Andrea
;Lynch, Erica Nicola
2026
Abstract
In non-cirrhotic primary biliary cholangitis, fatigue burden is similar to healthy controls and primary sclerosing cholangitis, but its phenotype is predominantly muscular (approximately 69%), independent of sex, age-adjusted employment, or routine disease metrics; daytime sleepiness and sleep duration are low/normal, and chronotype clusters in the intermediate range, with age - not disease - driving greater morningness. Primary sclerosing cholangitis shows a similar (weaker) direction of effect. These findings support routine fatigue phenotyping and muscle-focused interventions over cholestasis-directed therapies, and argue for objective endpoints (e.g., 31phosphorus magnetic resonance spectroscopy, actigraphy) in future trials.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



